**ANEXO III**

**Revisiones Bibliográficas encontradas en nuestra búsqueda**

|  |  |
| --- | --- |
| Alzheimer's disease in the omics era. Sancesario GM et Al. | 2018 |
| [Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. Portelius E et Al.](https://www.ncbi.nlm.nih.gov/pubmed/28942688) | **2017** |
| [Evolving Relevance of Neuroproteomics in Alzheimer's Disease. Lista S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/28508359) |
| [The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Westwood S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/28441961) |
| [Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid. Bastos P et Al.](https://www.ncbi.nlm.nih.gov/pubmed/28393582) |
| [Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA et Al.](https://www.ncbi.nlm.nih.gov/pubmed/28353223) |
| Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Baldacci F et Al. |
| Proteomic Substrate Identification for Membrane Proteases in the Brain. Müller SA et Al. | **2016** |
| Proteomics as an innovative tool to investigate frontotemporal disorders. Agresta AM et Al. |
| [Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Moya-Alvarado G et Al.](https://www.ncbi.nlm.nih.gov/pubmed/26657538) |
| [Neuroproteomic profiling of human body fluids. Häggmark A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/26286680) |
| [Advancing cerebrospinal fluid biomarker discovery by mass spectrometry. Gobom J et Al.](https://www.ncbi.nlm.nih.gov/pubmed/26477620) | **2015** |
| [Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids. Galozzi S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/26153725) |
| [Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review. Strac DS et Al.](https://www.ncbi.nlm.nih.gov/pubmed/25751428) |
| [Explorative and targeted neuroproteomics in Alzheimer's disease. Brinkmalm A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/25619854) |
| [Cerebrospinal fluid peptides as potential Parkinson diseasebiomarkers: a staged pipeline for discovery and validation. Shi M et Al.](https://www.ncbi.nlm.nih.gov/pubmed/25556233) |
| [The critical need for defining preclinical biomarkers in Alzheimer's disease. Fiandaca MS et Al.](https://www.ncbi.nlm.nih.gov/pubmed/24924671) | **2014** |
| [Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. Lista S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/24807087) |
| [Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Liu Y et Al.](https://www.ncbi.nlm.nih.gov/pubmed/24806343) |
| [Cerebrospinal fluid biomarkers of Alzheimer's disease. Xiaojing Sui et Al.](https://www.ncbi.nlm.nih.gov/pubmed/24733653) |
| [Role of proteomics in biomarker discovery: prognosis and diagnosis of neuropsychiatric disorders. Patel S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/24629185) |
| [Bi-level multi-source learning for heterogeneous block-wise missing data. Xiang S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/23988272) |
| [Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Keeney JT et Al.](https://www.ncbi.nlm.nih.gov/pubmed/23027708) | **2013** |
| [Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Zürbig P et Al.](https://www.ncbi.nlm.nih.gov/pubmed/23160951) | **2012** |
| [Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease. Grela A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/22868793) |
| [[An overview of biomarkers in Alzheimer's disease]. Rong XF et Al.](https://www.ncbi.nlm.nih.gov/pubmed/22811995) |
| [Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Lista S et Al.](https://www.ncbi.nlm.nih.gov/pubmed/22743552) |
| [A window into the heterogeneity of human cerebrospinal fluidAβ peptides. Ghidoni R et Al.](https://www.ncbi.nlm.nih.gov/pubmed/21876644) | **2011** |
| [Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going? Lewczuk P et Al.](https://www.ncbi.nlm.nih.gov/pubmed/21819301) |
| [Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. Ghidoni R et Al.](https://www.ncbi.nlm.nih.gov/pubmed/21709402) |
| [Systems biology of Alzheimer's disease: how diverse molecular changes result in memory impairment in AD. Juhász G et Al.](https://www.ncbi.nlm.nih.gov/pubmed/21333708) |
| [Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Choi YS et Al.](https://www.ncbi.nlm.nih.gov/pubmed/21142892) | **2010** |
| [Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K et Al.](https://www.ncbi.nlm.nih.gov/pubmed/20157306) |
| [Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Cedazo-Minguez A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/19796673) |
| [Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Maurer MH et Al.](https://www.ncbi.nlm.nih.gov/pubmed/19116946) |
| [Biomarker discovery in neurodegenerative diseases: a proteomic approach. Shi M et Al.](https://www.ncbi.nlm.nih.gov/pubmed/18938247) | **2009** |
| [[CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders]. Gabelle A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/18808768) |
| [Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Hampel H et Al.](https://www.ncbi.nlm.nih.gov/pubmed/18631949) | **2008** |
| [Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. Portelius E et Al.](https://www.ncbi.nlm.nih.gov/pubmed/18466053) |
| [Neurochemical dementia diagnostics: State of the art and research perspectives. Lewczuk P et Al.](https://www.ncbi.nlm.nih.gov/pubmed/18271068) |
| [Current state and future directions of neurochemical biomarkers for Alzheimer's disease. De Jong D et Al.](https://www.ncbi.nlm.nih.gov/pubmed/17970699) | **2007** |
| Biomarkers for Alzheimer's disease. Ward M et Al. |
| [CSF-studies in neuropsychiatric disorders. Raedler TJ et Al.](https://www.ncbi.nlm.nih.gov/pubmed/16807525) | **2006** |
| [Genetics, transcriptomics, and proteomics of Alzheimer's disease. Papassotiropoulos A et Al.](https://www.ncbi.nlm.nih.gov/pubmed/16669732) |
| [Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach. D’Ascenzo M et Al.](https://www.ncbi.nlm.nih.gov/pubmed/16372405) | **2005** |
| [CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Blennow K et Al.](https://www.ncbi.nlm.nih.gov/pubmed/16149870) |
| [CSF proteome: a protein repository for potential biomarker identification. Romeo MJ et Al.](https://www.ncbi.nlm.nih.gov/pubmed/15966853) |
| [Biomarkers for Alzheimer's disease--clinical needs and application. Galasko D et Al.](https://www.ncbi.nlm.nih.gov/pubmed/16556965) |
| [The use of proteomics in biomarker discovery in neurodegenerative diseases. Davidsson P et Al](https://www.ncbi.nlm.nih.gov/pubmed/15920295) |  |
| [[The role of lipid metabolism in Alzheimer's disease]. Kamino K et Al.](https://www.ncbi.nlm.nih.gov/pubmed/12373863) | **2002** |

**Artículos excluidos de nuestro estudio.**

|  |  |
| --- | --- |
| 3. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Bos I et Al. | 2018 |
| 11. Metabolic network failures in Alzheimer's disease: A biochemical road map. Toledo JB et Al. | **2017** |
| 16. Identification of discriminative imaging proteomics associations in alzheimer's disease via a novel sparse correlation model. Yan J et Al. |
| 29. Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Galasko D et Al. | **2015** |
| 41. Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors. Barucker C et Al. |
| 52. Translational proteomics in Alzheimer's disease and related disorders. Ghidoni R et Al. | **2013** |
| 55. Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. Cologna SM et Al. | **2012** |
| 58. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Yuan L et Al. |
| 70. Ethylenediaminetetraacetic acid increases identification rate of phosphoproteomics in real biological samples. Nakamura T et Al. | **2010** |
| 71. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Oh JH et Al. |
| 75. [Proteomic analysis of protein profiles in some pathological stages of the human organism]. Kossowska B et Al. | **2009** |
| 77. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Perrin RJ et Al. |
| 79. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. Evans BA et Al. |
| 81. Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. Myint KT et Al. |
| 84. iTRAQPak: an R based analysis and visualization package for 8-plex isobaric protein expression data. D’Ascenzo M et Al. | **2008** |
| 87. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Choe L et Al. | **2007** |
| 91. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimerdementia in patients with mild cognitive impairment. Simonsen AH et Al. |
| 96. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Abdi F et Al. | **2006** |
| 97. Proteome studies of CSF in AD patients. Davidsson P et Al. |

**Artículos que no usan LCR de muestra.**

|  |  |
| --- | --- |
| 5. Identification of prefrontal cortex protein alterations in Alzheimer's disease. Garranzo-Asensio M et Al. | 2018 |
| 7. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. Dayon L et Al. | **2017** |
| 9. A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs). Shirotani K et Al. |
| 13. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease. Kitamura Y et Al. |
| 19. Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease. Jammeh E et Al. | **2016** |
| 40. Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease. Watt AD et Al. | **2015** |
| 42. A candidate plasma protein classifier to identify Alzheimer's disease. Zhao X et Al. |
| 56. Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Simon R et Al. | **2012** |
| 57. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Soares HD et Al. |
| 74. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Soares HD et Al. | **2009** |

**Artículos no descargables.**

|  |  |
| --- | --- |
| 18. Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. Russell CL et Al. | 2017 |
| 32. Biomarkers in Sporadic and Familial Alzheimer's Disease. Lista S et Al. | **2015** |
| 59. Can apolipoproteins and complement factors be biomarkers of Alzheimer's disease? Manral P et Al. | **2012** |
| 80. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. Ghidoni R et Al. | **2009** |
| 82. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM et Al. | **2008** |
| 90. Proteomic discovery of CSF biomarkers for Alzheimer's disease. Zhang J et Al. | **2007** |
| 98. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. Zhang J et Al. | **2005** |
| 100. Biomarkers for Alzheimer's disease--clinical needs and application. Galasko D et Al. |
| 101. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Zhang J et Al. |
| 103. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Carrette O et Al. | **2003** |
| 104. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Choe LH et Al. | **2002** |

**Artículos con una única proteína a analizar**

|  |  |
| --- | --- |
| 12. Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker &amp; Lifestyle Flagship Study of Ageing (AIBL). Cardoso BR et Al. | 2017 |
| 27. CSF N-glycoproteomics for early diagnosis in Alzheimer's disease. Palmigiano A et Al. | **2016** |
| 35. Dickkopf-related protein 3 is a potential Aβ-associated protein in Alzheimer's Disease. Bruggink KA et Al. | **2015** |
| 36. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. Savage MJ et Al. |
| 47. Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer's diseaseand mild cognitive impairment. Poulsen K et Al. | **2014** |
| 63. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. Darreh-Shori T et Al. | **2012** |
| 82. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM et Al. | **2008** |
| 89. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. Lee JW et Al. | **2007** |
| 94. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Biroccio A et Al. | **2006** |

**Artículos que sólo analizaban Aβ-amiloide, Tau-P y Tau-T.**

|  |  |
| --- | --- |
| 10. Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Sjödin S et Al. | 2017 |
| 8. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Skillbäck T et Al. |
| 14. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Van Waalwijk van Doorn LJ et Al. |
| 23. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Oeckl P et Al. | **2016** |
| 24. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Rudinskiy N et Al. |
| 31. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Rogeberg M et Al. | **2015** |
| 44. Identification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches. Philibert KD et Al. | **2014** |
| 54. Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. Albertini V et Al. | **2012** |
| 66. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Halim A et Al. | **2011** |
| 68. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. Abraham JD et Al. |
| 69. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Craig-Schapiro R et Al. | **2010** |
| 72. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Portelius E et Al. |
| 73. Analysis of human tau in cerebrospinal fluid. Hanisch K et Al. |
| 88. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Maler JM et Al. | **2007** |